Drugs / Artacent®
Artacent®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04457752 Comparator | Sep 2020 → Mar 2022 | chronic ulcer of skin | SerenaGroup, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Artacent | “A novel dual layer amniotic membrane (DLAM, Artacent™, Tides Medical. Lafayette, LA) potentially can increase the delivery of growth factors due to its double layer of amniotic...” NCT04457752 ↗ |
| Known as | DLAM | “A novel dual layer amniotic membrane (DLAM, Artacent™, Tides Medical. Lafayette, LA) potentially can increase the delivery of growth factors due to its double layer of amniotic...” NCT04457752 ↗ |
| Known as | Dual Layer Amniotic Membrane | “A novel dual layer amniotic membrane (DLAM, Artacent™, Tides Medical. Lafayette, LA) potentially can increase the delivery of growth factors due to its double layer of amniotic...” NCT04457752 ↗ |
| Modality | Other / unclassified | “Artacent® is a double layer of dehydrated amniotic membrane.” NCT04457752 ↗ |
| Route | Topical | “It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers.” NCT04457752 ↗ |